Pharmaceutical firm with lab in Durham wins $77.2M federal contract for flu drug development
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
DURHAM, N.C. - BioCryst Pharmaceuticals, which has a lab in Durham, has won a $77.2 million contract from the federal government for further development of a potential flu drug called Peramivir.
The company also received a request for proposal from the Department of Health and Human Services for a supply of the drug to treat critically ill influenza patients. Somewhere between 1,000 and 40,000 doses could be ordered.
Use of the drug would be approved under a so-called emergency use authorization.
BioCryst (Nasdaq: BCRX) is based in Birmingham, Ala.
The Department of Health and Human Services is funding the research. BioCryst has already received a $102.6 million contract, that one having been awarded in 2007. The first contract covered early-phase clinical trials.
The new contract is for more testing that could lead to drug approval by the FDA.
Copyright 2012 WRAL Tech Wire. All rights reserved.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
The Skinny
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO